Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Orion Office REIT Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 32.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ONL | |
|---|---|---|
Market Cap | $5.07B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $29.41 | $3.04 |
52-Week Low | $20.06 | $1.93 |
Enterprise Value | $4.19B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
